Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

Mogensen AW et al. The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer ...

Ian Lavery says a constituent named Harry has been forced to travel almost 200 miles for cancer care, despite a mothballed ...

Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining ...

Aetna Life Insurance Co. received a federal judge’s first approval for a settlement valued at more than $3.4 million and ...

Experts from CO Architects, SOM, UW Health, City of Hope, and E4H discuss design trends shaping cancer care facility projects ...

Aetna Life Insurance Co. agreed to pay more than $3.4 million to settle a proposed class action by prostate cancer patients ...

4 June 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today ...

(HealthDay News) — Acupuncture may reduce nocturia in patients treated for prostate cancer, according to a research letter published in JAMA Oncology. Researchers conducted a randomized trial to ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson & Johnson’s Akeega is giving the class a win in ...

"CAN-2409 immunotherapy could represent the first new therapy for men with localized prostate cancer in over 20 years," wrote the authors. Adding aglatimagene besadenovec (CAN-2409) to standard of ...